A First-in-Human Randomized, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Oral Dose Study of Novel Imidazolopiperazine KAF156 To Assess Its Safety, Tolerability, and Pharmacokinetics in Healthy Adult Volunteers

KAF156 belongs to a new class of antimalarial, the imidazolopiperazines, and is currently in clinical development for the treatment of uncomplicated malaria. This first-in-human, single- and multiple-ascending-dose study in 70 healthy male volunteers determined the maximum oral dose of KAF156 tolera...

Descripción completa

Detalles Bibliográficos
Autores principales: Leong, F. Joel, Zhao, Rong, Zeng, Shuqi, Magnusson, Baldur, Diagana, Thierry T., Pertel, Peter
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2014
Materias:
Clinical Therapeutics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249437/
https://www.ncbi.nlm.nih.gov/pubmed/25136017
http://dx.doi.org/10.1128/AAC.03478-14

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4249437/
https://www.ncbi.nlm.nih.gov/pubmed/25136017
http://dx.doi.org/10.1128/AAC.03478-14

Ejemplares similares